> Individualized treatment plans using checkpoint inhibitor combinations, biotech therapies, etc are for few select individuals with A LOT of money.

This is the first step in the commoditization of any new treatment, no? Initially expensive but that creates competition to bring the price down.

[Maybe not in the US though because the customer cannot select their supplier]